ClinicalTrials.gg
Not yet recruitingNCT07620548Updated Oct 20, 2026

Laser Interstitial Thermal Therapy (LiTT) With Cemiplimab or Other Chemotherapy in Recurrent Glioblastomas

A Phase 2 interventional study of NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy and Cemiplimab in Glioblastoma, Glioblastoma, IDH-wildtype and Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, sponsored by Washington University School of Medicine. Not yet recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Washington University School of Medicine · Phase 2, Interventional, and Treatment

How we know

Updated Oct 20, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Glioblastoma by Washington University School of Medicine — 5 open to participants now, 7 under way, none of them phase 3. Glioblastoma · Washington University School of Medicine.

Planned enrollment
2nd of 16
99 · median 31
Started
2026
with 2 others
Phase 2
5 of 19
2 open now
Registered
19th of 19
by date

Among the 19 studies in Glioblastoma by Washington University School of Medicine, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 in phase 2, and was the 19th registered.

Glioblastoma

2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

5 of the 19 studies in Glioblastoma by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Glioblastoma by Washington University School of Medicine, or all of them as a file.
02

Study summary

This study will assess the therapeutic efficacy of the combination of Laser Interstitial Thermal Therapy (LiTT) with adjuvant cemiplimab compared to the therapeutic efficacy of the combination of LiTT with physician's choice of adjuvant chemotherapy in patients with recurrent glioblastoma. Patients will be enrolled and randomized on a 2:1 ratio to either the experimental arm (LiTT + cemiplimab) or the control arm (LiTT + physician/s choice chemotherapy).

03

Conditions studied

  • Glioblastoma
  • Glioblastoma, IDH-wildtype
  • Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype

Keywords

  • GBM
  • Recurrent
  • IDH-wt
  • IDH-wildtype
  • Glioblastoma
  • Immunotherapy
  • LiTT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed WHO grade 4 GBM (IDH-wt). Note: GBM variants, including histone-mutant and molecular-defined gliomas per WHO 2021 are allowed. Any number of recurrences are permitted.
  • Unequivocal evidence of tumor progression as documented on the screening .
  • At least 12 weeks post-completion of standard frontline therapy. Standard frontline therapy in this population includes maximal feasible surgical resection (biopsy alone is allowed), radiotherapy, and temozolomide chemotherapy. There is no restriction on the number of adjuvant temozolomide cycles.
  • Candidate for LITT based on the size, location, and shape of the recurrent tumor as determined by the performing neurosurgeon. Surgical resection/debulking prior to LITT is allowed per standard of care but is not required; if the patient undergoes resection or debulking, it must have occurred at least 3 weeks prior to the start of any study treatment.
  • At least 18 years of age.
  • performance status ≥ 60%
  • Adequate bone marrow and organ function as defined below:

    • ≥ 1.5 K/cumm
    • ≥ 100 K/cumm
    • ≥ 9.0 g/dL
    • Total ≤ 1.5 x IULN
    • (SGOT)/ALT(SGPT) ≤ 3.0 x IULN
    • > 30 mL/min by Cockcroft-Gault
    • or PT ≤ 1.5 x IULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
    • aPTT ≤ 1.5 x IULN (unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants)
  • The effects of cemiplimab on the developing human fetus are unknown. For this reason, people of and people able to father a child must agree to use adequate prior to study entry, for the duration of study participation, and for 4 months after completion of study participation (for patients in the Experimental Arm) OR 14 days after completion of study participation (for people of childbearing potential in the Control Arm) or 4 months (for people able to father a child in the Control Arm).
  • Ability to understand and willingness to sign an IRB approved written document. Legally authorized representatives may sign and give informed consent on behalf of study participants.

Exclusion criteria

Exclusion Criteria:

  • Received prior treatment with any anti-angiogenic agent (including bevacizumab) within 3 months of date of surgery (LITT). (Note: bevacizumab is otherwise permitted when used outside this window for cerebral edema.)
  • Received prior treatment with an , anti-PD-L1, anti-PD-L2, anti-CD127, or anti-CTLA-4 antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
  • Received prior treatment with a monoclonal antibody within 4 weeks prior to the first day of study treatment.
  • Received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to the first day of study treatment.
  • Has not recovered (i.e., grade 1 or baseline) from adverse events caused by anti-cancer agents administered no more than 4 weeks prior to consent. Note: patients with ≤ grade 2 neuropathy are an exception to this criterion. Note: if a patient underwent major surgery, they must have recovered adequately from the toxicity and/or complications prior to the first day of study treatment.
  • Candidate for curative resection or urgent surgical procedure(s) needed.
  • Presence of brainstem lesions or lesions that are \< 5 mm from the hypophysis or cranial nerves.
  • Multifocal glioma that is bilateral. Patients with unilateral multifocal gliomas may be eligible if their multifocal disease can be treated effectively and safely in a single LITT procedure. Note: Corpus callosal tumors are eligible even if they are bilateral as long as they satisfy the size and shape limits of LITT as determined by the performing neurosurgeon.
  • Presence of .
  • Recent (within 8 weeks) history of CNS hemorrhage unless the hemorrhage is located within the tumor that will be removed en total during surgical debulking or ablated during LITT.
  • Requires therapeutic doses of anticoagulants unless anticoagulation can be safely discontinued before surgery per standard practice or an IVC filter can be used in place of anticoagulation. Patients are permitted to resume anticoagulation following LITT at the discretion of their treating physician.
  • Received prior local therapy (stereotactic radiosurgery, brachytherapy, or carmustine wafers) to the proposed area of LITT.
  • Received a or live-attenuated vaccine within 28 days prior to the first day of study treatment. Received COVID-19 vaccine within 7 days of first dose.
  • Currently receiving any other agents or has participated in a study of an investigational agent or device within 3 weeks of the first day of study treatment.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to study agents used in the study.
  • Dexamethasone > 4 mg at the time of consent.
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 7 days prior to the first dose of trial treatment (with the exception of daily dexamethasone ≤ 4 mg).
  • History of immune related pneumonitis or (non-infectious) interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease in the last 5 years.
  • Uncontrolled intercurrent illness including, but not limited to: ongoing or active infection or infection requiring hospitalization or treatment with IV anti-infectives within 14 days of first dose, myocardial infarction within 12 months of first dose, symptomatic congestive heart failure, unstable angina pectoris, acute coronary syndrome within 12 months of first dose, or stroke within 12 months of first dose, or cardiac arrhythmia. Function Classification of class II, II, or IV are exclusionary.
  • Has an active disease requiring systemic treatment within the past 2 years (i.e. with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Pregnant and/or breastfeeding. People of must have a negative pregnancy test within 14 days of study entry and again within 72 hours of initiation of cemiplimab (if applicable).
  • Active or latent tuberculosis.
  • History of infection if not on effective anti-retroviral therapy with undetectable viral load for 6 months. Patients with HIV who are receiving effective anti-retroviral therapy and have had an undetectable viral load for at least 6 months are eligible. HIV testing not required in the absence of known history of infection.
  • Evidence of chronic virus (HBV) that is detectable on suppressive therapy. Patients with evidence of chronic HBV infection with undetectable HBV viral load on suppressive therapy are eligible. HBV testing not required in the absence of known history of infection.
  • History of virus (HCV) infection that has not been cured or that has a detectable viral load. Patients with a history of HCV that has been treated and cured are eligible. Patients with HCV infection who are currently on treatment and have an undetectable HCV viral load are eligible. HCV testing not required in the absence of known history of infection.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
99 participants (estimated)

Study arms

  • Experimental
    Experimental Arm: LiTT + Cemiplimab

    Patients in the Experimental Arm will receive adjuvant cemiplimab (at a dose of 350 mg intravenously (IV)) every 3 weeks after LiTT for a maximum total of 36 months (or until disease progression or intolerable adverse event). The first adjuvant dose of cemiplimab must be given within 14 days post-LiTT.

    Device: NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy · Drug: Cemiplimab

  • Active comparator
    Control Arm: LiTT + adjuvant chemotherapy

    Patients in the Control Arm will undergo LiTT, then will receive adjuvant chemotherapy (chosen by their treating physician) for up to 12 months as per standard of care (SOC), starting within 14 days post-LiTT.

    Device: NeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy · Drug: Chemotherapy

Interventions

  • DeviceNeuroBlate® Laser Ablation Laser Interstitial Thermal Therapy

    LiTT, or magnetic resource imaging (MRI)-guided laser ablation, is a minimally invasive surgery approved for cytoreductive treatment of brain tumors. It employs a small incision in the scalp and skull, through which a thin laser probe is inserted and guided by MRI imaging to the core of a tumor mass where it delivers hyperthermic ablation from the core to the rim.

    Also known as: LiTT

  • Cemiplimab is a programmed death receptor-1 (PD-1)-blocking antibody that is administered intravenously at 350mg over 30 minutes every 3 weeks on an outpatient basis.

    Also known as: Libtayo®

  • DrugChemotherapy

    Adjuvant chemotherapy will be decided by the physician's choice of best fit by patient, including the agent(s), dosing, and schedule.

06

What researchers measure

Primary outcomes

  1. Progression-free survival (PFS) at Month 6 (PFS6)

    PFS6 as defined from the time of treatment start to the time of progression (based on clinical assessment and imaging per Immunotherapy Response Assessment in Neuro-Oncology (iRANO)) or death, whichever is earlier, or last follow-up if neither progression nor death event is observed. PFS6 will be estimated as the empirical PFS probability at Month 6 using the Kaplan-Meier method.

    Time frame: Start of treatment through 6 months after start of treatment (month 6)

  2. Overall survival (OS) at Month 18 (OS18)

    OS as defined from the time of treatment start to the time of death or last follow up if surviving; OS-18 is further estimated as the empirical OS probability at Month 18 using the Kaplan-Meier method.

    Time frame: Start of treatment through 18 months after start of treatment (month 18)

Secondary outcomes

  1. Median Progression-Free Survival (PFS) as determined using the Kaplan-Meier method

    PFS as defined from the time of treatment start to the time of progression (based on clinical assessment and imaging per Immunotherapy Response Assessment in Neuro-Oncology (iRANO)) or death, whichever is earlier, or last follow-up if neither progression nor death event is observed.

    Time frame: Start of treatment through 1 year after completion of treatment or progression (up to 3 years)

  2. Median Overall Survival (OS) as determined using the Kaplan-Meier method

    OS as defined from the time of treatment start to the time of death or last follow up if surviving.

    Time frame: Start of treatment through 1 year after completion of treatment or progression (up to 3 years)

  3. Objective Response Rate (ORR)

    Proportion of patients achieving Complete Response (CR) or Partial Response (PR) by iRANO criteria. CR - Requires all of the following: complete disappearance of all enhancing measurable and non-measurable disease sustained for at least 4 weeks. No new lesions; stable or improved non-enhancing (T2/FLAIR) lesions. Patients must be off corticosteroids (or on physiologic replacement doses only) and stable or improved clinically. PR - Requires all of the following: ≥ 50% decrease compared with baseline in the sum of products of perpendicular diameters of all measurable enhancing lesions sustained for at least 4 weeks. No progression of nonmeasurable disease. Stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan; the corticosteroid dose at the time of the scan evaluation should be no greater than the dose at time of baseline scan. Stable or improved clinically.

    Time frame: Start of treatment through completion of treatment or progression (up to 2 years)

  4. Disease control rate (DCR)

    DCR, defined as proportion of patients achieving Complete Response (CR), Partial Response (PR), or Stable Disease (SD) by iRANO criteria.

    Time frame: Start of treatment through 1 year after completion of treatment or progression (up to 3 years)

  5. Duration of response (DoR)

    DoR, defined as the time period from when a patient first achieves a positive response (complete or partial response) by iRANO criteria to when disease progresses or death.

    Time frame: From first positive response (6 weeks after start of treatment) through 1 year after completion of treatment or progression (up to 3 years)

  6. Number of participants with adverse events as defined by CTCAE v5.0

    Time frame: Start of treatment through 90 days after last dose of treatment (up to 27 months)

  7. Changes in Health-related quality of life (HRQoL) as measured by the EORTC QLQ C30

    HRQoL changes over the timeline of the trial will be assessed by the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ C30) questionnaire which examines 5 major domains (physical, role, emotional, social, cognitive). The questionnaire is composed of 30 questions. Twenty-eight questions follow a 4-point scale ranked as follows: 1 Not at all, 2 A Little, 3 Quite a bit, and 4 Very much. Two questions follow a 7-point Likert scale from 1 Very Poor to 7 Excellent. The higher the score, the higher quality of life.

    Time frame: Baseline through end of treatment (up to 3 years)

  8. Changes in neurologic symptoms as measured by the EORTC QLQ BN20

    Changes in patient's neurologic symptoms across the timeline of the trial will be assessed via the EORTC QLQ BN20 questionnaire, which is specifically formulated to assess symptoms and quality of life of brain cancer patients. The questionnaire is composed of 20 questions that follow a 4-point scale ranked as follows: 1 Not at all, 2 A Little, 3 Quite a bit, and 4 Very much. Separate symptom and quality of life scores are calculated according to the validated measure. The higher the score on the symptom scale generally means a greater severity of symptoms and a higher score on the functionality scale generally means a higher quality of life.

    Time frame: Baseline through end of treatment (up to 2 years)

07

Study locations

2 sites
  • Mayo Clinic
    Rochester, Minnesota 55902, United States
    • Jian L Campian, M.D., Ph.D. · Contactcampian.jian@mayo.edu · 507-512-8186
    • Jian L Campian, M.D., Ph.D. · Principal investigator
  • Washington University School of Medicine
    St Louis, Missouri 63110, United States
    • Omar H Butt, M.D., Ph.D. · Contactomarhbutt@wustl.edu · 215-279-3388
    • Omar H Butt, M.D., Ph.D. · Principal investigator
    • Milan Chheda, M.D. · Sub investigator
    • Tanner M Johanns, M.D., Ph.D. · Sub investigator
    • Albert H Kim, M.D., Ph.D. · Sub investigator
    • Eric Leuthardt, M.D. · Sub investigator
    • Dimitrios Mathios, M.D. · Sub investigator
    • Jingqin (Rosy) Luo, Ph.D. · Sub investigator
    • Yu (Jade) Tao, M.D. · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlies the results reported will be shared (after deidentification) at time of final reporting/article. This will further include study protocol and statistical plan.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 3 months and ending 5 years following study article publication

Access criteria: Researchers who provide a methodologically sound proposal. If approved, a data access/transfer agreement to be completed. Proposal requests to be emailed to corresponding article author. Link will be included on study conclusion

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for May 2031, 54 months later.

Of 197 non-industry phase 2 interventional studies under Glioblastoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 54 months is close to that.

Counting every sponsor, half of 248 studies reached it within 55 months; a quarter within 40 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: start Aug 2026 → Nov 2026, primary completion Feb 2031 → May 2031 and completion Aug 2032 → Nov 2032.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2026
First posted
Jun 2, 2026
StartEst.
Nov 30, 2026was Aug 2026
Primary completionEst.
May 31, 2031was Feb 2031
CompletionEst.
Nov 30, 2032was Aug 2032
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 31, 2026→Nov 30, 2026
Oct 20, 2026
Primary completion
Feb 28, 2031→May 31, 2031
Oct 20, 2026
Study completion
Aug 31, 2032→Nov 30, 2032
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Start date Aug 31, 2026→Nov 30, 2026
    Primary completion Feb 28, 2031→May 31, 2031
    Study completion Aug 31, 2032→Nov 30, 2032
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07620548
Responsible party
Sponsor
First posted
Jun 2, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
May 31, 2031 (estimated)
Completion
Nov 30, 2032 (estimated)
Last update
Oct 20, 2026

Study contacts

Omar H Butt, M.D., Ph.D.
Contact
omarhbutt@wustl.edu
215-279-3388
Omar H Butt, M.D., Ph.D.
principal investigator · Washington University School of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion